CatalystFDA/Bio

INTELLIA RISES ON FDA PRIORITY REVIEW FOR ONE-TIME HEREDITARY ANGIOEDEMA THERAPY - SEEKINGALPHA

FDA priority review accelerates approval odds for Intellia’s one-time hereditary angioedema therapy.

What changed

FDA priority review accelerates approval odds for Intellia’s one-time hereditary angioedema therapy.

Why it matters

FDA priority review accelerates approval odds for Intellia’s one-time hereditary angioedema therapy. — impact context not separately stored; see What changed.

Sources

seekingalpha